Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Lentivectors
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Lentivectors

[0171-K002] Cas9 Nuclease Lentiviral Vector - 10 µg
Cas9 Nuclease Lentiviral Vector - 10 µg
522.25 € 522.25 EUR
[0500-LVP941-P] CRE_TRE-GFP (Puro)  Lentivector - 1x107 IFU/ml x 200ul
CRE_TRE-GFP (Puro) Lentivector - 1x107 IFU/ml x 200ul
820.00 € 820.0 EUR
[0500-ULVP-337] CRE-2A-GFP (CMV-Bsd), Ultra titer Lentivector - 1 x109 IFU/ml x 50 ul
CRE-2A-GFP (CMV-Bsd), Ultra titer Lentivector - 1 x109 IFU/ml x 50 ul
1,450.00 € 1450.0 EUR
[0500-CMV-Null-RB-PBS] CMV Control Lentivector, RFP-Bsd, x10^7
CMV Control Lentivector, RFP-Bsd, x10^7
978.00 € 978.0 EUR
[0500-CMV-Null-RB] CMV Control  lentiviral Particle (RFP-Bsd), 1 x107 IFU/ml x 200ul
CMV Control lentiviral Particle (RFP-Bsd), 1 x107 IFU/ml x 200ul
365.00 € 365.0 EUR
[0171-162860610395] CLDN6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 1ug.
CLDN6 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 1ug.
614.00 € 614.0 EUR
[0171-LV116481-158790610395] CENPK Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 1.0 µg DNA
CENPK Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 1.0 µg DNA
322.50 € 322.5 EUR
[0171-5818061] CEACAM7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
CEACAM7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
520.00 € 520.0 EUR
[0171-15814061] CEACAM3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
CEACAM3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
520.00 € 520.0 EUR
[0171-15800061] CEACAM1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
CEACAM1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
375.00 € 375.0 EUR
[01717-156691110502] CDH3 sgRNA CRISPR All-in-One Lentivector set (Human)
CDH3 sgRNA CRISPR All-in-One Lentivector set (Human)
2,000.00 € 2000.0 EUR
[0171-15543111] CD40 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
CD40 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
580.00 € 580.0 EUR
[0171-154960610395] CD209 Lentivector SpeciesHuman (BC110615) (1)FeaturesCMV-RFP Reporter (04)Vector/Virus/CellLentiviral Vector (95)
CD209 Lentivector SpeciesHuman (BC110615) (1)FeaturesCMV-RFP Reporter (04)Vector/Virus/CellLentiviral Vector (95)
1,188.00 € 1188.0 EUR
[0171-154960610495] CD209 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
CD209 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
645.00 € 645.0 EUR
[0171-LV658] Blank 5’ UTR Reporter Lentiviral Vector (Luc) - 1.0 μg
Blank 5’ UTR Reporter Lentiviral Vector (Luc) - 1.0 μg
320.00 € 320.0 EUR
[0171-LV657] Blank 5’ UTR Reporter Lentiviral Vector (GFP) - 1.0 μg
Blank 5’ UTR Reporter Lentiviral Vector (GFP) - 1.0 μg
320.00 € 320.0 EUR
[0171-LV014] BbsI Linearized iLenti siRNA Vector - 25 ul
BbsI Linearized iLenti siRNA Vector - 25 ul
710.00 € 710.0 EUR
[0171-304190610396] (LVP227170) MRGPRX2 Lentivector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 2 x 200 ul @ 10⁷ IU/ml
(LVP227170) MRGPRX2 Lentivector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) - 2 x 200 ul @ 10⁷ IU/ml
886.00 € 886.0 EUR
[0171-278500610295] (LV210827) LYRM4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) - 1.0 µg DNA
(LV210827) LYRM4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) - 1.0 µg DNA
931.00 € 931.0 EUR
[0171-278500610195] (LV210826) LYRM4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) - 1.0 µg DNA
(LV210826) LYRM4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) - 1.0 µg DNA
620.00 € 620.0 EUR
  • 1
  • 2
  • 3
  • 4

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)